vTv Therapeutics (VTVT) Share-based Compensation (2015 - 2026)

vTv Therapeutics has disclosed Share-based Compensation across 12 years of filings, most recently posting $1.4 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $1.4 million, up 70.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.4 million (up 29.85% YoY), and the FY2025 annual result was $3.8 million, up 36.92% from the prior year.
• Share-based Compensation came in at $1.4 million for Q1 2026 at vTv Therapeutics, up from $1.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $1.4 million in Q1 2026 to a low of $167000.0 in Q2 2022.
• The 5-year median for Share-based Compensation is $476000.0 (2022), against an average of $633529.4.
• Across the five-year window, Share-based Compensation sank 70.72% in 2022 and soared 269.55% in 2025, its largest moves.
• vTv Therapeutics' Share-based Compensation stood at $291000.0 in 2022, then soared by 38.49% to $403000.0 in 2023, then soared by 104.71% to $825000.0 in 2024, then gained by 24.24% to $1.0 million in 2025, then jumped by 35.41% to $1.4 million in 2026.
• The last three Share-based Compensation figures came in at $1.4 million (Q1 2026), $1.0 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.